Jesus Berdeja, MD
Enriched profileDirector, Multiple Myeloma Research · Sarah Cannon Research Institute
Jesus Berdeja is Director, Multiple Myeloma Research at Sarah Cannon Research Institute. OpenAlex indexes 531 publications with 18,892 citations (h-index 59); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Jesús G. Berdeja, MD, is Director, Multiple Myeloma Research at Sarah Cannon Research Institute / Tennessee Oncology. The public record shows 531 publications with 18,892 citations (h-index 59), centered on Leukemia (AML/ALL/CML/CLL), Multiple Myeloma, MDS / MPN. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 30 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 30 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Caribou Biosciences, Inc.
Industry payments
Updated 14 Oct 2026
30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
74.6%CD38-directed Cytolytic Antibody73.2%Daratumumab100%Part B, office-administered≥15 patientsThalidomide Analog1.2%Revlimid81%Pomalyst19%Part D<11 patients+ 2 more classes in this area
Anti-infectives
24.7%Human Immunoglobulin G24.6%Immune globulin100%Part B, office-administered≥27 patientsShort-acting sulfonamides0.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Dermatology
0.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.4%Acyclovir100%Part D≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Blood cancer journal
Article2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
Article2025
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Jesus-G-Berdeja-2152888066
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/BerdejaJesus
Mentions by others
where others cite or feature them- X / Twitter
x.com/NashvilleHeme/status/1975565272770597305
- X / Twitter
x.com/theMMRF/status/1887501939962712126
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Residency
Internal Medicine, University of California, San Francisco
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Fellowship
Medical Oncology and Hematology, Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Board Certified
Internal Medicine, Medical Oncology, and Hematology - American Board of Internal Medicine (ABIM)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - BS
Stanford University (undergraduate)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Member
International Myeloma Society (IMS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Member
International Myeloma Working Group (IMWG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Member
American Society of Hematology (ASH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Editorial Board
Blood Cancer Journal (Nature)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nature.com ↗ - Member
Clinical Trials Myeloma Intergroup Committee and CIBMTR Plasma Cell Working Group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- Formerly
Stem Cell and Bone Marrow Transplant Program and Division of Hematology/Oncology, Loma Linda University
2008provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Sarah Cannon Center for Blood Cancers
Nashville, TN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Spigel, MD
Sarah Cannon Research Institute
Howard Burris, MD
Sarah Cannon Research Institute
John Hainsworth, MD
Sarah Cannon Research Institute
Denise A. Yardley
Sarah Cannon Research Institute
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center